Yang ES - Search Results

1

Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy.

Si Y, Xu Y, Guan J, Chen K, Kim S, Yang ES, Zhou L, Liu XM. Si Y, et al. Among authors: yang es. Eng Life Sci. 2020 Oct 7;21(1-2):37-44. doi: 10.1002/elsc.202000027. eCollection 2021 Jan. Eng Life Sci. 2020. PMID: 33531889 Free PMC article.

2

Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.

Nowsheen S, Cooper T, Stanley JA, Yang ES. Nowsheen S, et al. Among authors: yang es. PLoS One. 2012;7(10):e46614. doi: 10.1371/journal.pone.0046614. Epub 2012 Oct 11. PLoS One. 2012. PMID: 23071597 Free PMC article.

3

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer.

Si Y, Zhang Y, Ngo HG, Guan JS, Chen K, Wang Q, Singh AP, Xu Y, Zhou L, Yang ES, Liu XM. Si Y, et al. Among authors: yang es. Cancers (Basel). 2021 Jul 26;13(15):3749. doi: 10.3390/cancers13153749. Cancers (Basel). 2021. PMID: 34359650 Free PMC article.

4

Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers.

Si Y, Zhang Y, Guan JS, Ngo HG, Totoro A, Singh AP, Chen K, Xu Y, Yang ES, Zhou L, Liu R, Liu XM. Si Y, et al. Among authors: yang es. Vaccines (Basel). 2021 Aug 10;9(8):882. doi: 10.3390/vaccines9080882. Vaccines (Basel). 2021. PMID: 34452008 Free PMC article.

5

Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.

Clark CA, Yang ES. Clark CA, et al. Among authors: yang es. Front Oncol. 2021 Sep 24;11:703802. doi: 10.3389/fonc.2021.703802. eCollection 2021. Front Oncol. 2021. PMID: 34631532 Free PMC article. Review.

6

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.

Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES. Stringer-Reasor EM, et al. Among authors: yang es. Breast Cancer Res. 2021 Mar 4;23(1):30. doi: 10.1186/s13058-021-01408-9. Breast Cancer Res. 2021. PMID: 33663560 Free PMC article. Clinical Trial.

7

Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer.

Song PN, Mansur A, Lu Y, Della Manna D, Burns A, Samuel S, Heinzman K, Lapi SE, Yang ES, Sorace AG. Song PN, et al. Among authors: yang es. Cancers (Basel). 2022 Feb 17;14(4):1015. doi: 10.3390/cancers14041015. Cancers (Basel). 2022. PMID: 35205763 Free PMC article.

8

A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer.

Gong C, Cheng Z, Yang Y, Shen J, Zhu Y, Ling L, Lin W, Yu Z, Li Z, Tan W, Zheng C, Zheng W, Zhong J, Zhang X, Zeng Y, Liu Q, Huang RS, Komorowski AL, Yang ES, Bertucci F, Ricci F, Orlandi A, Franceschini G, Takabe K, Klimberg S, Ishii N, Toss A, Tan MP, Cherian MA, Song E. Gong C, et al. Among authors: yang es, yang y. Sci China Life Sci. 2022 Nov;65(11):2205-2217. doi: 10.1007/s11427-022-2104-3. Epub 2022 May 13. Sci China Life Sci. 2022. PMID: 35579777

9

Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models.

Mansur A, Song PN, Lu Y, Burns AC, Sligh L, Yang ES, Sorace AG. Mansur A, et al. Among authors: yang es. Biomedicines. 2023 Jul 25;11(8):2090. doi: 10.3390/biomedicines11082090. Biomedicines. 2023. PMID: 37626587 Free PMC article.

10

Discussion of PARP inhibitors in cancer therapy.

Wielgos M, Yang ES. Wielgos M, et al. Among authors: yang es. Pharm Pat Anal. 2013 Nov;2(6):755-66. doi: 10.4155/ppa.13.53. Pharm Pat Anal. 2013. PMID: 24237241 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

329 results

Search Page